The radiopharmaceutical CDMO market is experiencing strong growth, driven by the expanding clinical and commercial pipeline of targeted radiotherapies and radiodiagnostics. Rising demand for specialized manufacturing capabilities, stringent regulatory requirements, and the need for reliable isotope handling are encouraging pharmaceutical and biotechnology companies to increasingly outsource development and production. Growing investments in isotope production infrastructure, GMP-compliant manufacturing facilities, and global supply chain networks are further supporting market expansion.
The radiopharmaceutical CDMO market is experiencing strong growth, driven by the expanding clinical and commercial pipeline of targeted radiotherapies and radiodiagnostics. Rising demand for specialized manufacturing capabilities, stringent regulatory requirements, and the need for reliable isotope handling are encouraging pharmaceutical and biotechnology companies to increasingly outsource development and production. Growing investments in isotope production infrastructure, GMP-compliant manufacturing facilities, and global supply chain networks are further supporting market expansion.